TY - JOUR
T1 - Association of Demographic Factors and Infantile Hemangioma Characteristics with Risk of PHACE Syndrome
AU - PHACE Retrospective Study Group
AU - Cotton, Colleen H.
AU - Ahluwalia, Jusleen
AU - Balkin, Daniel M.
AU - Frieden, Ilona J.
AU - Haggstrom, Anita N.
AU - Castelo-Soccio, Leslie A.
AU - Liy-Wong, Carmen
AU - Pope, Elena
AU - Steiner, Jack E.
AU - Siegel, Dawn H.
AU - Fernandez-Faith, Esteban
AU - Morel, Kimberly D.
AU - Lauren, Christine T.
AU - Garzon, Maria C.
AU - Mancini, Anthony J.
AU - Chamlin, Sarah L.
AU - Tollefson, Megha M.
AU - Liang, Marilyn G.
AU - Delano, Sophia
AU - Glick, Sharon A.
AU - Hogeling, Marcia
AU - Barrio, Victoria R.
N1 - Funding Information:
reported receiving grants from Pediatric Dermatology Research Alliance (PeDRA) during the conduct of the study and other support from Pierre Fabre Food and Beverage outside the submitted work. Dr Frieden reported receiving consulting fees from Venthera Biobridge, serving on the Novartis Advisory Board, receiving consulting fees from Pfizer, serving on the Data Safety Monitoring Board outside the submitted work, and serving as a physician adviser for the PHACE syndrome community and as president of PeDRA. Dr Pope reported receiving consulting fees from Novartis, Boehringer Ingelheim, and Sanofi outside the submitted work. Dr Siegel reported receiving grants from SID-SUN, consulting fees from Merck, and honoraria from UpToDate outside the submitted work. Dr Garzon reported serving as an investigator for the Pediatric Trials Network Topical Timolol Study 2017-2020 during the conduct of the study. Dr Mancini reported serving on the advisory boards of Verrica, ParaPRO, Cassiopea, and Novartis and receiving speaker fees from Sanofi Regeneron outside the submitted work. Dr Glick reported participating in a conference on hemangioma sponsored by Pierre Fabre Pharmaceuticals, which paid expenses outside the submitted work. No other disclosures were reported.
Publisher Copyright:
© 2021 American Medical Association. All rights reserved.
PY - 2021/8
Y1 - 2021/8
N2 - Importance: A 2010 prospective study of 108 infants estimated the incidence of PHACE (posterior fossa malformations, hemangioma, arterial anomalies, cardiac defects, eye anomalies) syndrome to be 31% in children with facial infantile hemangiomas (IHs) of at least 22 cm2. There is little evidence regarding the associations among IH characteristics, demographic characteristics, and risk of PHACE syndrome. Objectives: To evaluate demographic characteristics and comorbidities in a large cohort of patients at risk for PHACE syndrome and assess the clinical features of large head and neck IH that may be associated with a greater risk of a diagnosis of PHACE syndrome. Design, Setting, and Participants: This multicenter, retrospective cohort study assessed all patients with a facial, head, and/or neck IH who were evaluated for PHACE syndrome from August 1, 2009, to December 31, 2014, at 13 pediatric dermatology referral centers across North America. Data analysis was performed from June 15, 2017, to February 29, 2020. Main Outcomes and Measures: The main outcome was presence or absence of PHACE syndrome. Data included age at diagnosis, sex, patterns of IH presentation (including size, segment location, and depth), diagnostic procedures and results, and type and number of associated anomalies. Results: A total of 238 patients (mean [SD] age, 2.96 [4.71] months; 184 [77.3%] female) were included in the analysis; 106 (44.5%) met the criteria for definite (n = 98) or possible (n = 8) PHACE syndrome. A stepwise linear regression model found that a surface area of 25 cm2or greater (odds ratio [OR] 2.99; 95% CI, 1.49-6.02) and involvement of 3 or more locations (OR, 17.96; 95% CI, 6.10-52.85) to be statistically significant risk factors for PHACE syndrome. Involvement of the parotid gland (OR, 0.39; 95% CI, 0.18-0.85) and segment S2 (OR, 0.38; 95% CI, 0.16-0.91) was associated with a lower risk. Race and ethnicity may also be associated with PHACE syndrome risk, although more studies are needed. Conclusions and Relevance: This cohort study further described factors associated with both a higher and lower risk of PHACE syndrome. The presence of multiple anatomical sites and large surface area were associated with greater risk, whereas S2 or parotid IHs were associated with lower, but still potential, risk. These findings can help in counseling families and decision-making regarding evaluation of infants with large head and neck IHs..
AB - Importance: A 2010 prospective study of 108 infants estimated the incidence of PHACE (posterior fossa malformations, hemangioma, arterial anomalies, cardiac defects, eye anomalies) syndrome to be 31% in children with facial infantile hemangiomas (IHs) of at least 22 cm2. There is little evidence regarding the associations among IH characteristics, demographic characteristics, and risk of PHACE syndrome. Objectives: To evaluate demographic characteristics and comorbidities in a large cohort of patients at risk for PHACE syndrome and assess the clinical features of large head and neck IH that may be associated with a greater risk of a diagnosis of PHACE syndrome. Design, Setting, and Participants: This multicenter, retrospective cohort study assessed all patients with a facial, head, and/or neck IH who were evaluated for PHACE syndrome from August 1, 2009, to December 31, 2014, at 13 pediatric dermatology referral centers across North America. Data analysis was performed from June 15, 2017, to February 29, 2020. Main Outcomes and Measures: The main outcome was presence or absence of PHACE syndrome. Data included age at diagnosis, sex, patterns of IH presentation (including size, segment location, and depth), diagnostic procedures and results, and type and number of associated anomalies. Results: A total of 238 patients (mean [SD] age, 2.96 [4.71] months; 184 [77.3%] female) were included in the analysis; 106 (44.5%) met the criteria for definite (n = 98) or possible (n = 8) PHACE syndrome. A stepwise linear regression model found that a surface area of 25 cm2or greater (odds ratio [OR] 2.99; 95% CI, 1.49-6.02) and involvement of 3 or more locations (OR, 17.96; 95% CI, 6.10-52.85) to be statistically significant risk factors for PHACE syndrome. Involvement of the parotid gland (OR, 0.39; 95% CI, 0.18-0.85) and segment S2 (OR, 0.38; 95% CI, 0.16-0.91) was associated with a lower risk. Race and ethnicity may also be associated with PHACE syndrome risk, although more studies are needed. Conclusions and Relevance: This cohort study further described factors associated with both a higher and lower risk of PHACE syndrome. The presence of multiple anatomical sites and large surface area were associated with greater risk, whereas S2 or parotid IHs were associated with lower, but still potential, risk. These findings can help in counseling families and decision-making regarding evaluation of infants with large head and neck IHs..
UR - http://www.scopus.com/inward/record.url?scp=85108569410&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85108569410&partnerID=8YFLogxK
U2 - 10.1001/jamadermatol.2021.1901
DO - 10.1001/jamadermatol.2021.1901
M3 - Article
C2 - 34132754
AN - SCOPUS:85108569410
SN - 2168-6068
VL - 157
SP - 932
EP - 939
JO - JAMA Dermatology
JF - JAMA Dermatology
IS - 8
ER -